Duncan MaskellNon-executive director
Duncan Maskell is the University of Cambridge's Senior Pro-Vice Chancellor (Planning and Resources), the Marks & Spencer Professor of Farm Animal Health, Food Science and Food Safety at the Department of Veterinary Medicine and a Fellow of Wolfson College.
Duncan was a co-founder of Arrow Therapeutics Ltd which was sold to AstraZeneca in 2007 and, more recently, of Discuva Limited, Bactevo Limited and Polypharmakos Limited. He has been a consultant to a number of SMEs and start-ups and is a Non-Executive Director of Genus plc, an animal breeding company that is a constituent of the FTSE 250.
Duncan has spent his research career working on bacterial infectious diseases in humans and other animals. He has worked on many different pathogens, using molecular biology and genomics to understand how they interact with their hosts. This has led to over 250 papers and many collaborations worldwide. He is or has been a member of many different scientific advisory boards, government committees, Research Council grant and strategic committees, and editorial boards, both in the UK and internationally.
Duncan was awarded his MA and PhD from the University of Cambridge and worked for Wellcome Biotech on vaccines for typhoid fever and whooping cough before taking up positions at the University of Oxford and Imperial College, London. He returned to Cambridge to his current Professorship in 1996 and was elected to a Fellowship of the Academy of Medical Sciences in 2011.
From October 2018 Duncan has been appointed Vice-Chancellor of the University of Melbourne.